Literature DB >> 24430101

Acute illness associated with use of pest strips - seven U.S. States and Canada, 2000-2013.

Rebecca J Tsai, Jennifer Sievert, Joanne Prado, Kaci Buhl, Dave L Stone, Mathias Forrester, Shelia Higgins, Yvette Mitchell, Abby Schwartz, Geoffrey M Calvert.   

Abstract

Dichlorvos-impregnated resin strips (DDVP pest strips) are among the few organophosphate products still available for indoor residential use. The residential uses for most other organophosphate products, including most DDVP products, were canceled because they posed unreasonable risks to children. DDVP pest strips act by inhibiting acetylcholinesterase activity in the brain and nerves of insect pests and are designed to gradually release DDVP vapor for up to 4 months. Acute illnesses in humans associated with nonlethal acute exposures usually resolve completely, but recovery is not always rapid. To assess the frequency of acute illnesses associated with DDVP pest strips, cases from 2000 through June 2013 were sought from the 12 states that participate in the Sentinel Event Notification System for Occupational Risks (SENSOR)-Pesticides Program, the National Pesticide Information Center (NPIC), and Health Canada.* A total of 31 acute DDVP pest strip-related illness cases were identified in seven U.S. states and Canada. The majority of these illnesses resulted from use of the product in commonly occupied living areas (e.g., kitchens and bedrooms), in violation of label directions. Although 26 of the 31 cases involved mild health effects of short duration, five persons had moderate health effects. Illnesses caused by excess exposure to DDVP pest strips can be reduced by educating the public about the proper usage of DDVP pest strips and with improvements in label directions.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24430101      PMCID: PMC4584652     

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


Dichlorvos-impregnated resin strips (DDVP pest strips) are among the few organophosphate products still available for indoor residential use. The residential uses for most other organophosphate products, including most DDVP products, were canceled because they posed unreasonable risks to children (1). DDVP pest strips act by inhibiting acetylcholinesterase activity in the brain and nerves of insect pests and are designed to gradually release DDVP vapor for up to 4 months (2,3). Acute illnesses in humans associated with nonlethal acute exposures usually resolve completely, but recovery is not always rapid (2). To assess the frequency of acute illnesses associated with DDVP pest strips, cases from 2000 through June 2013 were sought from the 12 states that participate in the Sentinel Event Notification System for Occupational Risks (SENSOR)–Pesticides Program, the National Pesticide Information Center (NPIC), and Health Canada.* A total of 31 acute DDVP pest strip–related illness cases were identified in seven U.S. states and Canada. The majority of these illnesses resulted from use of the product in commonly occupied living areas (e.g., kitchens and bedrooms), in violation of label directions. Although 26 of the 31 cases involved mild health effects of short duration, five persons had moderate health effects. Illnesses caused by excess exposure to DDVP pest strips can be reduced by educating the public about the proper usage of DDVP pest strips and with improvements in label directions. Cases were defined and classified based on the strength of evidence for DDVP exposure and health effects consistent with and following exposure to DDVP pest strips.† Information was collected on demographic characteristics, event location, health effects, outcomes (e.g., hospitalization), contributing factors, reporting source, illness severity,§ and work-relatedness. From 2000 to 2013, a total of 31 (30 possible and one probable) cases of acute DDVP pest strip–related illness were identified in the United States (24 cases) and Canada (seven). The 24 U.S. cases were reported to SENSOR or NPIC from seven states; the seven Canada cases were reported to Health Canada from across the country. Twenty-six (84%) of the 31 cases were classified as of low severity, and 24 (77%) of the patients were female (Table). Among the 22 cases for which age was known, the mean age of patients was 48 years. Twenty-four (77%) of the exposures occurred in private residences. The most commonly reported affected body systems and their symptoms were neurologic (68%) (e.g., headache), respiratory (55%) (e.g., dyspnea), and gastrointestinal (42%) (e.g., nausea) (Table). Five of the 31 persons had health effects considered moderate, including asthma attack, respiratory distress requiring hospitalization, paresthesias, and incoordination.
TABLE

Characteristics of patients (N = 31) with acute dichlorvos (DDVP) pest strip–related illness — seven U.S. states and Canada, 2000–2013

CharacteristicNo.(%)
Age group (yrs)
 ≤191(3)
 20–6424(77)
 ≥654(13)
 Unknown2(6)
Sex
 Female24(77)
 Male7(23)
Body system/Organ affected *
 Neurologic21(68)
 Respiratory17(55)
 Gastrointestinal13(42)
 Other11(35)
 Skin7(23)
 Eye7(23)
Case classification
 Possible30(97)
 Probable1(3)
Severity of illness
 Low26(84)
 Moderate5(16)
Route of exposure §
 Respiratory28(90)
 Dermal5(16)
Location of exposure
 Home24(77)
 Workplace (Store/Office)3(10)
 Other (Boat/Car)3(10)
 Unknown1(3)
Label violation status
 Applied DDVP in areas occupied by humans ≥4 hours/day18(58)
 Excessive application2(6)
 Undetermined11(35)

Sum exceeds 100% because some patients had more than one affected body system/organ.

Low severity cases usually resolve without treatment and cause minimal time lost from work (<3 days). Moderate severity cases are not life threatening but require medical treatment and result in <6 days lost from work.

The sum exceeds 100% because two cases had both routes of exposure.

Insufficient data were available to determine whether the DDVP strip usage resulted in a label violation.

A total of 20 (65%) of the 31 cases involved label¶ violations, mostly use of DDVP pest strips in areas occupied by persons ≥4 hours/day. For the remaining 11 cases, information was not sufficient to determine if whether usage of DDVP pest strips resulted in a label violation (Table). Contributing factors other than using strips in occupied areas included excessive application (two cases), placing strips in sealed bags to treat infested items (four), lack of skin protection (e.g., gloves or prompt skin washing) (four), placing strips in closets and pantries (three), cutting and tearing strips into smaller pieces (three), and using a heater and fan to accelerate vapor dissemination from strips (three). In the 11 cases for which it was unclear whether a label violation had occurred, exposure might have resulted from misunderstanding of label directions. Currently in the United States, DDVP pest strips are offered in three different sizes: 16 g, 65 g, and 80 g. Label directions differ across sizes, but also can differ across brands of the same size. For example, whereas all labels specify that one 65 g or 80 g strip will treat up to 900–1,200 cubic feet, not all labels advise against using the product in smaller spaces, nor do they all provide a clear warning against excessive application. Moreover, some labels list offices as appropriate places for strip placement even though these are typically occupied for ≥4 hours/day. Finally, although some strips are approved for bed bug control, the directions for use are substantially different for bed bugs versus other insect infestations, which might confuse some users and lead to improper use.** Preventing DDVP pest strip–related illnesses requires educating the public regarding how to correctly use DDVP pest strips and how to control insect pests using methods with the least possible health and environmental hazards.
  2 in total

1.  Biomonitoring of Exposure to Organophosphate Pesticides: McKelvey et al. Respond.

Authors:  Wendy McKelvey; J Bryan Jacobson; Daniel Kass; Dana B Barr
Journal:  Environ Health Perspect       Date:  2014-07       Impact factor: 9.031

Review 2.  Organophosphate exposures during pregnancy and child neurodevelopment: Recommendations for essential policy reforms.

Authors:  Irva Hertz-Picciotto; Jennifer B Sass; Stephanie Engel; Deborah H Bennett; Asa Bradman; Brenda Eskenazi; Bruce Lanphear; Robin Whyatt
Journal:  PLoS Med       Date:  2018-10-24       Impact factor: 11.613

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.